Third-Line Treatment Options for Metastatic Colorectal Cancer
Panelists discuss the selection of third-line therapies, including FTD/TPI, regorafenib, and others, based on survival data, safety, and patient quality of life.
Therapeutic Landscape
The therapeutic landscape for metastatic colorectal cancer is outlined, including available agents such as trifluridine/tipiracil (FTD/TPI), regorafenib, and newer targeted therapies.
The RECOURSE trial demonstrates improvements in overall survival and a manageable safety profile for FTD/TPI.
Treatment Choice
Clinicians emphasize the importance of balancing efficacy with tolerability to ensure quality of life for heavily pretreated patients.
- FTD/TPI
- Regorafenib
- Newer targeted therapies
Author's summary: Experts discuss third-line treatment options for metastatic colorectal cancer.